Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in HIV-positive individuals with metabolic complications.

Cade WT, Reeds DN, Overton ET, Herrero P, Waggoner AD, Laciny E, Bopp C, Lassa-Claxton S, Gropler RJ, Peterson LR, Yarasheski KE.

HIV Clin Trials. 2013 Nov-Dec;14(6):303-12. doi: 10.1310/hct1406-303.


Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.

Yarasheski KE, Cade WT, Overton ET, Mondy KE, Hubert S, Laciny E, Bopp C, Lassa-Claxton S, Reeds DN.

Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E243-51. doi: 10.1152/ajpendo.00468.2010. Epub 2010 Oct 19.


Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis.

Cade WT, Reeds DN, Overton ET, Herrero P, Waggoner AD, Davila-Roman VG, Lassa-Claxton S, Gropler RJ, Soto PF, Krauss MJ, Yarasheski KE, Peterson LR.

Cardiovasc Diabetol. 2011 Dec 8;10:111. doi: 10.1186/1475-2840-10-111.


Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

Circulation. 2009 Apr 21;119(15):2069-77. doi: 10.1161/CIRCULATIONAHA.108.803916. Epub 2009 Apr 6.


Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.

Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y.

Am J Hypertens. 2005 Jul;18(7):949-57.


Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.

Magkos F, Brennan A, Sweeney L, Kang ES, Doweiko J, Karchmer AW, Mantzoros CS.

Metabolism. 2011 Jul;60(7):1045-9. doi: 10.1016/j.metabol.2010.10.002. Epub 2010 Nov 16.


Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.

Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F.

Diabetologia. 2013 Oct;56(10):2153-63. doi: 10.1007/s00125-013-2976-z. Epub 2013 Jun 30.


Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging.

Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

J Am Coll Cardiol. 2009 Oct 13;54(16):1524-32. doi: 10.1016/j.jacc.2009.04.074.


Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes.

McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF.

Diabetes Care. 2005 May;28(5):1145-50.


Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction.

Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A.

Circulation. 2002 Dec 10;106(24):3126-32.


Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome.

Straznicky NE, Grima MT, Sari CI, Eikelis N, Lambert GW, Nestel PJ, Richards K, Dixon JB, Schlaich MP, Lambert EA.

Metabolism. 2015 Jul;64(7):797-803. doi: 10.1016/j.metabol.2015.03.006. Epub 2015 Mar 18.


A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes.

Hughes AD, Park C, March K, Coady E, Khir A, Chaturvedi N, Thom SA.

Int J Cardiol. 2013 Aug 20;167(4):1329-32. doi: 10.1016/j.ijcard.2012.03.179. Epub 2012 Apr 21.


The role of a structured exercise training program on cardiac structure and function after acute myocardial infarction: study protocol for a randomized controlled trial.

Fontes-Carvalho R, Sampaio F, Teixeira M, Gama V, Leite-Moreira AF.

Trials. 2015 Mar 12;16:90. doi: 10.1186/s13063-015-0612-6.


Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.

Hällsten K, Virtanen KA, Lönnqvist F, Janatuinen T, Turiceanu M, Rönnemaa T, Viikari J, Lehtimäki T, Knuuti J, Nuutila P.

Diabet Med. 2004 Dec;21(12):1280-7.


Improvement of left ventricular function by lifestyle intervention in obesity: contributions of weight loss and reduced insulin resistance.

Kosmala W, O'Moore-Sullivan T, Plaksej R, Przewlocka-Kosmala M, Marwick TH.

Diabetologia. 2009 Nov;52(11):2306-16. doi: 10.1007/s00125-009-1507-4. Epub 2009 Sep 2.


Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size.

Ye Y, Keyes KT, Zhang CF, Perez-Polo JR, Lin Y, Birnbaum Y.

Cardiovasc Drugs Ther. 2010 Apr;24(2):107-20. doi: 10.1007/s10557-010-6227-y.


Pioglitazone therapy in mouse offspring exposed to maternal obesity.

Kalanderian A, Abate N, Patrikeev I, Wei J, Vincent KL, Motamedi M, Saade GR, Bytautiene E.

Am J Obstet Gynecol. 2013 Apr;208(4):308.e1-7. doi: 10.1016/j.ajog.2013.01.013. Epub 2013 Jan 10.


Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes.

Dorkhan M, Dencker M, Stagmo M, Groop L.

Cardiovasc Diabetol. 2009 Mar 20;8:15. doi: 10.1186/1475-2840-8-15.


Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(16):1-167. Epub 2005 Oct 1.

Items per page

Supplemental Content

Write to the Help Desk